Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Lipari Mining and SpurChain Partner to Tokenize Natural Diamond Production (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for... see more

Recent & Breaking News (NDAQ:VNDA)

Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference

PR Newswire 1 day ago

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

PR Newswire 8 days ago

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

PR Newswire October 22, 2025

Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

PR Newswire October 8, 2025

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

PR Newswire October 1, 2025

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

PR Newswire September 25, 2025

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

PR Newswire August 28, 2025

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

PR Newswire August 28, 2025

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

PR Newswire August 18, 2025

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

PR Newswire July 31, 2025

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

PR Newswire July 23, 2025

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

PR Newswire June 10, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

PR Newswire May 27, 2025

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

PR Newswire May 16, 2025

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

PR Newswire May 7, 2025

Vanda Announces Bysanti(TM) NDA Filing; FDA Decision Expected in Early 2026

PR Newswire May 5, 2025

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

PR Newswire May 2, 2025

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

PR Newswire April 23, 2025

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

PR Newswire April 7, 2025

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti(TM) for the Treatments of Acute Bipolar I Disorder and Schizophrenia

PR Newswire March 31, 2025